Cancer drug discovery through collaboration.
It has been two decades since cancer was first described as a genetic disease and researchers offered the promise of early diagnosis and targeted therapies. Today, most cancer patients still await life-saving treatments. Genomics and other '-omics' technologies have revealed a complexity among cancers that makes almost any tumour genetically unique; as a consequence, effective targeted therapies might be suitable only for small subgroups of patients. We suggest that by merging and organizing their core competencies, academia, biotechnology companies and the pharmaceutical industry can address existing bottlenecks in anticancer drug discovery and development.
Lengauer
Christoph
C
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, Maryland 21231, USA. lengauer@jhmi.edu <lengauer@jhmi.edu>
Diaz
Luis A
LA
Saha
Saurabh
S
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000138:chemical synthesis*; D002626:Chemistry, Pharmaceutical / Q000379:methods* / Q000639:trends; D003299:Cooperative Behavior; D015195:Drug Design; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents